PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis

Annals of Neurology

Volumn 56, Issue 2, 2004, Pages 240-248

  Bilak, Masako ^a   Wu, Liejun ^a   Wang, Qian ^a   Haughey, Norman ^a   Conant, Katherine ^a   St Hillaire, Coryse ^a   Andreasson, Katrin ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLOOXYGENASE 2; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; PROSTAGLANDIN E RECEPTOR; PROSTANOID RECEPTOR; BUTAPROST; DRUG DERIVATIVE; ENZYME INHIBITOR; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN H; ONCOPROTEIN; PERTUSSIS TOXIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SULPROSTONE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL LOSS; CELL SURVIVAL; CHRONIC TOXICITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME MECHANISM; MOTONEURON; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; SPINAL CORD NERVE CELL; VENTRAL ROOT; ANIMAL; CELL COUNT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM; METHODOLOGY; NEWBORN; NONPARAMETRIC TEST; ORGAN CULTURE TECHNIQUE; PATHOPHYSIOLOGY; PHYSIOLOGY; SPINAL CORD; SPRAGUE DAWLEY RAT;

ALPROSTADIL; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; CELL COUNT; CYCLIC AMP; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; IMMUNOHISTOCHEMISTRY; MOTOR NEURONS; NEUROFILAMENT PROTEINS; ORGAN CULTURE TECHNIQUES; PERTUSSIS TOXIN; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E; SPINAL CORD; STATISTICS, NONPARAMETRIC;

EID: 3843129633     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20179     Document Type: Article

References (66)

1. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
2. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-1468.
3. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
4. Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
5. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
6. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002;26:459-470.
7. Kriz JNM, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:268-278.
8. Weydt P, Weiss MD, Moller T, Carter GT. Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis. Curr Opin Invest Drugs 2002;3:1720-1724.
9. Drachman DB, Rothstein JD. Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann Neurol 2000;48:792-795.
10. Drachman DB, Frank K, Dykes-Hoberg M, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002;52:771-778.
11. Yamagata K, Andreasson K, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993;11:371-386.
12. Nakayama M, Uchimura K, Zhu RL, et al. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA 1998;95:10954-10959.
13. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997;17:2746-2755.
14. Feng ZH, Wang TG, Li DD, et al. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyll, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 2002;329:354-358.
15. Teismann P, Tieu K, Choi DK, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003;100:5473-5478.
16. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998;87:319-324.
17. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661-690.
18. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993;90:6591-6595.
19. Corse AM, Bilak MM, Bilak SR, et al. Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration. Neurobiol Dis 1999;6:335-346.
20. Bilak MM, Becerra SP, Vincent AM, et al. Identification of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons. J Neurosci 2002;22:9378-9386.
21. Kiriyama M, Ushikubi F, Kobayashi T, et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997;122:217-224.
22. Bilak MM, Corse AM, Bilak SR, et al. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J Neuropathol Exp Neurol 1999;58:719-728.
23. Bilak MM, Shifrin DA, Corse AM, et al. Neuroprotective utility and neurotrophic action of neurturin in postnatal motor neurons: comparison with GDNF and persephin. Mol Cell Neurosci 1999;13:326-336.
24. Bilak MM, Kuncl RW. Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons. Neuroreport 2001;12:2531-2535.
25. Anderson CM, Bridges RJ, Chamberlin AR, et al. Differing effects of substrate and non-substrate transport inhibitors on glutamate uptake reversal. J Neurochem 2001;79:1207-1216.
26. Gardiner PJ. Characterization of prostanoid relaxant/inhibitory receptors using a highly selective agonist, TR4979. Br J Pharmacol 1986;87:45-56.
27. Hanson M, Shen S, Wiemelt A, et al. Cyclic AMP elevation is sufficient to promote the survival of spinal motor neurons in vitro. J. Neurosci 1998;18:7361-7371.
28. Seamon KB, Daly JW. Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res 1986:20:1-150.
29. Chijiwa T, Mishima A, Hagiwara N, et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthetized selective inhibitor of cyclic AMP-dependent protein kinase (H89) of PC12D pheochromocytoma cells. J Biol Chem 1990;265:5267-5272.
30. Schaaf TK, Bindra JS, Eggler JF, et al. N-(methanesulfonyl)-16- phenoxyprostaglandincarboxamides: tissue-selective, uterine stimulants. J Med Chem 1981;24:1353-1359.
31. Irie A, Sugimoto Y, Namba T, et al. Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. Eur J Biochem 1993;217:313-318.
32. Sugimoto Y, Negishi M, Hayashi Y, et al. Two isoforms of the EP3 receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with Gi proteins. J Biol Chem 1993;268:2712-2718.
33. Nakamura T, Ui M. Simultaneous inhibitions of inositol phospholipid breakdown, arachidonic acid release, and histamine secretion in mast cells by islet-activating protein, pertussis toxin. A possible involvement of the toxin-specific substrate in the Ca2+-mobilizing receptor-mediated biosignaling system. J Biol Chem 1985;260:3584-3593.
34. Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001;11:297-305.
35. Bilak MM, Corse AM, Kuncl RW. Additivity and potentiation of IGF-I and GDNF in the complete rescue of postnatal motor neurons. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:83-91.
36. Delfs JR, Saroff DM, Nishida Y, et al. Effects of NMDA and its antagonists on ventral horn cholinergic neurons in organotypic roller tube spinal cord cultures. J Neural Transm 1997;104:31-51.
37. Rothstein JD, Bristol LA, Hosler B, et al. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci USA 1994;91:4155-4159.
38. Saroff D, Delfs J, Kurnetsov D, Geula C. Selective vulnerability of spinal cord motor neurons to non-NMDA toxicity. Neuroreport 2000;11:1117-1121.
39. Almer G, Guegan C, Teismann P, et al. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 2001;49:176-185.
40. Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 2001;57:952-956.
41. Almer G, Teismann P, Stevic Z, et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Ann Neurol 2002;58:1277-1279.
42. Pompl PN, Ho L, Bianchi M, et al. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB 2003;10:1096.
43. Dore S, Otsuka T, Mito T, et al. Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 2003;54:155-162.
44. Kunz T, Oliw E. The selective cyclooxygenase-2 inhibitor refecoxib reduces kainate-induced cell death in the rat hippocampus. Eur J Neurosci 2001;13:569-575.
45. Miettinen S, Fusco FR, Yrjanheikki J, et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci USA 1997;94:6500-6505.
46. Andreasson KI, Savonenko A, Vidensky S, et al. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci 2001;21:8198-8209.
47. McCullough L, Wu L, Haughey N, et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004;24:257-268.
48. Eling TE, Thompson DC, Foureman GL, et al. Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 1990;330:1-45.
49. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 1991;48:153-179.
50. Hastings TG. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995;64:919-924.
51. Mirjany M, Ho L, Pasinetti GM. Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J Pharmacol Exp Ther 2002;301:494-500.
52. Trifan OC, Smith RM, Thompson BD, Hla T. Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin- independent mechanism. J Biol Chem 1999;274:34141-34147.
53. Xiang Z, Ho L, Valdellon J, et al. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging 2002;23:327-334.
54. Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 2003;23:2557-2563.
55. Harris SG, Padilla J, Koumas L, et al. Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-50.
56. Ek M, Engblom D, Saha S, et al. Inflammatory response: pathway across the blood-brain barrier. Nature 2001;410:430-431.
57. Yamagata K, Matsumura K, Inoue W, et al. Coexpression of microsomal-type prostaglandin E synthase with cyclooxygenase-2 in brain endothelial cells of rats during endotoxin-induced fever. J Neurosci 2001;21:2669-2677.
58. Thery C, Dobbertin A, Mallat M. Downregulation of in vitro neurotoxicity of brain macrophages by prostaglandin E2 and a beta-adrenergic agonist. Glia 1994;11:383-386.
59. Caggiano AO, Kraig RP. Rostaglandin E2 and 4-aminopyridine prevent the lipopolysaccharide-induced outwardly rectifying potassium current and interleukin-1beta production in cultured rat microglia. J Neurochem 1998;70:2357-2368.
60. Zhang J, Rivest S. Anti-inflammatory effects of prostaglandin E2 in the central nervous system in response to brain injury and circulating lipopolysaccharide. J Neurochem 2001;76:855-864.
61. Minghetti L, Nicolini A, Polazzi E, et al. Inducible nitric oxide synthase expression in activated rat microglial cultures is down-regulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 1997;19:152-160.
62. Kim EJ, Kwon KJ, Park JY, et al. Neuroptotective effects of prostaglandin E2 or cAMP against microglial and neuronal free radical mediated toxicity associated with inflammation. J Neurosci Res 2002;70:97-107.
63. Almer G, Vukosavic S, Romero N, Przedborski S. Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1999;72:2415-2425.
64. Cassina P, Peluffo H, Pehar M, et al. Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis. J Neurosci Res 2002;67:21-29.
65. Caggiano AO, Kraig RP. Prostaglandin E receptor subtypes in cultured rat microglia and their role in reducing lipopolysaccharide-induced interleukin-1beta production. J Neurochem 1999;72:565-575.
66. Li M, Ona VO, Guegan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288:335-339.